NovoCure Limited (NVCR)
| Market Cap | 1.70B +5.8% |
| Revenue (ttm) | 699.19M +11.0% |
| Net Income | -148.57M |
| EPS | -1.31 |
| Shares Out | 116.45M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,022,286 |
| Open | 14.17 |
| Previous Close | 14.22 |
| Day's Range | 14.14 - 14.78 |
| 52-Week Range | 9.82 - 21.45 |
| Beta | 0.99 |
| Analysts | Buy |
| Price Target | 26.86 (+84.23%) |
| Earnings Date | Oct 29, 2026 |
About NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Lim... [Read more]
Financial Performance
In 2025, NovoCure's revenue was $655.35 million, an increase of 8.28% compared to the previous year's $605.22 million. Losses were -$136.23 million, -19.21% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for NVCR stock is "Buy." The 12-month stock price target is $26.86, which is an increase of 84.23% from the latest price.
News
Novocure receives approval for Optune Pax in Japan
Novocure (NVCR) announced that Japan’s Ministry of Health, Labour and Welfare approved Optune Pax for the treatment of adult patients diagnosed with unresectable locally advanced pancreatic cancer, co...
Novocure's Optune Pax® Receives Approval in Japan for the Treatment of Unresectable Locally Advanced Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for the treatment of adult patients diagnose...
Novocure to Report Third Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (Nasdaq: NVCR) will report financial results for the third quarter 2026 on October 29, 2026, before the U.S. financial markets open. Novocure management wi...
NovoCure Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Disciplined investment and cost controls have reignited GBM growth and enabled global expansion, with strong launches in pancreatic and lung cancer, especially in Japan. Profitability is within reach, and clinical trials are advancing, including new combination strategies with KRAS inhibitors.
NovoCure Transcript: Wells Fargo 21st Annual Healthcare Conference
Optune Pax's launch for pancreatic cancer exceeded expectations, with strong patient uptake and early payer coverage, while competitive therapies are not expected to significantly impact momentum. Expansion in Japan and Europe, pipeline progress, and disciplined financial management position the business for sustained growth.
Novocure Announces Upcoming Investor Events
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor events. Wells Fargo 21st Annual Healthcare Conference, September 9...
Oncology firm Novocure says cyberattack exposed US patient records
Oncology company Novocure said on Tuesday a cybersecurity incident involving unauthorized access to certain information systems in mid-August exposed internal records of more than 1,400 U.S. patient...
Novocure aware of unauthorized access to some information systems
In a regulatory filing, Novocure (NVCR) stated: “In mid-August 2026, NovoCure Limited through a subsidiary, became aware of unauthorized access to some of its information systems. Upon detecting the u...
Novocure price target raised to $20 from $18 at Wedbush
Wedbush raised the firm’s price target on Novocure (NVCR) to $20 from $18 and keeps a Neutral rating on the shares. The firm notes the company’s Q2 revenue of $183.6M…
Novocure price target raised to $52 from $46 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Novocure (NVCR) to $52 from $46 and keeps a Buy rating on the shares. The company reported a record revenue quarter driven…
NovoCure Earnings Call Transcript: Q2 2026
Record Q2 net revenues and active patients drove a 16% year-over-year revenue increase, with all product lines contributing to growth. Raised full-year guidance and achieved positive adjusted EBITDA, while advancing launches in the U.S., Europe, and Japan.
NovoCure Quarterly report: Q2 2026
NovoCure has published its Q2 2026 quarterly earnings report on July 23, 2026.
NovoCure Earnings release: Q2 2026
NovoCure released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
NovoCure Slides: Q2 2026
NovoCure has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Novocure raises FY26 revenue view to $710M-$725M from $690M-$710M
Raises FY26 adjusted EBITDA view to $0M-$15M from ($15M)-$0M.
Novocure reports Q2 EPS (13c), consensus (33c)
Reports Q2 revenue $183.6M, consensus $172.44M. “This was our strongest quarter to date, with record net revenues and active patients on therapy,” said Frank Leonard, CEO, Novocure (NVCR). “We continu...
Novocure Reports Second Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend su...
Novocure resumed with a Neutral at JPMorgan
JPMorgan resumed coverage of Novocure (NVCR) with a Neutral rating and $17 price target The firm believes the shares already price in credit for the company’s new launches. Published first…
Novocure to Report Second Quarter 2026 Financial Results
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2026 on July 23, 2026, before the U.S. financial markets open. Novocure management will...
Novocure announces Optune Pax received CE Mark
Novocure (NVCR) announced that Optune Pax has received CE Mark for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-pacl...
Novocure's Optune Pax® Receives CE Mark for the Treatment of Locally Advanced Pancreatic Cancer
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that Optune Pax® has received CE (Conformité Européenne) Mark for the treatment of adult patients with locally advanced panc...
Novocure Limited Investigation Initiated: SueWallSt Investigates the Officers and Directors of Novocure Limited (NVCR)
Novocure reported its Phase 3 TRIDENT Trial failed to achieve its primary endpoint of an increase in overall survival for patients at the start of chemoradiation. Shares were down more than 18% midday...
Novocure price target lowered to $46 from $48 at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar lowered the firm’s price target on Novocure (NVCR) to $46 from $48 and keeps a Buy rating on the shares. The firm reduced the company’s…